Jefferies upgraded Mesoblast (MESO) to Buy from Hold with a price target of A$3.30, up from A$3.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MESO:
- Mesoblast to Launch Pivotal Ryoncil® Trial for Severe aGvHD in Adults
- Mesoblast collaborating with BMT CTN on trial of Ryoncil in acute GvHD
- Mesoblast appoints James O’Brien as CFO
- Mesoblast Announces Director’s Share Acquisition and New Equity Issuance
- Mesoblast’s Promising Study on Chronic Low Back Pain Treatment: A Market Game Changer?